CAS NO: | 142561-96-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
rat liver squalene synthase inhibitor
Cas No. | 142561-96-4 |
别名 | 萨拉哥酸A,Squalestatin S1 |
化学名 | (1S,3S,4S,5R,6R,7R)-1-((4S,5R)-4-acetoxy-5-methyl-3-methylene-6-phenylhexyl)-6-(((4S,6S,E)-4,6-dimethyloct-2-enoyl)oxy)-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid |
Canonical SMILES | O[C@@H]1[C@H]([C@@]2([C@](C(O)=O)([C@H](O[C@@]1(CCC([C@H]([C@@H](CC3=CC=CC=C3)C)OC(C)=O)=C)O2)C(O)=O)O)C(O)=O)OC(/C=C/[C@H](C[C@H](CC)C)C)=O |
分子式 | C35H46O14 |
分子量 | 690.73 |
溶解度 | Soluble in ethanol, methanol, DMSO, DMF |
储存条件 | Store at -20℃,protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Ki: 78 pM for rat liver squalene synthase The zaragozic acids (ZAs), which is a family of fungal metabolites containing a novel 4,6,7-trihydroxy-2,8-dioxobicyclo[3.2.1]octane-3,4,5-tricarboxylic acid core, have been independently discovered by two separate groups via screening natural product sources to discover inhibitors of squalene synthase. In vitro: Zaragozic acid A, as well as it two analogs Zaragozic acid B and C were discovered from an unidentified sterile fungal culture, Spororniella intermedia, and Leptodontium elatius, respectively. Zaragozic acid A, B and C were reported to be three potent competitive inhibitors of rat liver squalene synthase with Ki values of 78 pM, 29 pM, and 45 pM, respectively. In addition, Zaragozic acid A, B and C could also inhibite cholesterol synthesis in Hep G2 cells [1]. In vivo: In the mouse model, zaragozic acid A was found to be an inhibitor of acute hepatic cholesterol synthesis (50% inhibitory dose of 200 μg/kg). The in-vivo inhibition of squalene synthase was accompanied by an accumulation of label from [3Hjmevalonate into farnesyl diphosphate, farnesol, as well as organic acids. In summary, these data showed the zaragozic acids were a new class of therapeutic agents with potential for the hypercholesterolemia treatment [1]. Clinical trial: Up to now, zaragozic acid A is still in the preclinical development stage. Reference: |